[go: up one dir, main page]

MA27443A1 - Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) - Google Patents

Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Info

Publication number
MA27443A1
MA27443A1 MA28157A MA28157A MA27443A1 MA 27443 A1 MA27443 A1 MA 27443A1 MA 28157 A MA28157 A MA 28157A MA 28157 A MA28157 A MA 28157A MA 27443 A1 MA27443 A1 MA 27443A1
Authority
MA
Morocco
Prior art keywords
tgf
thiazoles
transforming growth
inhibitors
oxazoles
Prior art date
Application number
MA28157A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27443A1 publication Critical patent/MA27443A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REVENDICATION DE PRIORITES US 18 Septembre 2002 60/412,120 US 16 Mai 2003 60/471,265 US 2 Juillet 2003 60/484,581 Voir en annexe le titre de l'invention et le texte de l'abrégé Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (TGF) Des oxazoles et thiazoles nouveaux, y compris leurs dérivés, des intermédiaires pour leur préparation, des compositions pharmaceutiques les contenant, et leur utilisation en médecine sont décrits. Les composés de la présente invention sont de puissants inhibiteurs de la voie de transmission de signal du facteur de croissance transformant ("TGF")-(bêta). Ils sont utiles dans le traitement de divers états pathologiques en rapport avec le TGF, comprenant, par exemple, le cancer et des maladies fibrotiques.
MA28157A 2002-09-18 2005-03-18 Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) MA27443A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
MA27443A1 true MA27443A1 (fr) 2005-07-01

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28157A MA27443A1 (fr) 2002-09-18 2005-03-18 Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Country Status (28)

Country Link
US (1) US7273936B2 (fr)
EP (1) EP1542994B1 (fr)
JP (1) JP4518956B2 (fr)
KR (1) KR20050057415A (fr)
CN (1) CN1681810A (fr)
AP (1) AP2005003261A0 (fr)
AR (1) AR041273A1 (fr)
AT (1) ATE430147T1 (fr)
AU (1) AU2003256003A1 (fr)
BR (1) BR0314383A (fr)
CA (1) CA2499429C (fr)
CO (1) CO5550473A2 (fr)
CR (1) CR7743A (fr)
DE (1) DE60327443D1 (fr)
EA (1) EA200500354A1 (fr)
ES (1) ES2323421T3 (fr)
HR (1) HRP20050250A2 (fr)
IS (1) IS7711A (fr)
MA (1) MA27443A1 (fr)
MX (1) MXPA05002332A (fr)
NO (1) NO20051838L (fr)
OA (1) OA12926A (fr)
PA (1) PA8582701A1 (fr)
PE (1) PE20040987A1 (fr)
PL (1) PL375975A1 (fr)
TW (1) TW200413362A (fr)
UY (1) UY27978A1 (fr)
WO (1) WO2004026863A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
OA12929A (en) * 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
AU2003263404A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
AR050917A1 (es) * 2004-08-13 2006-12-06 Amphora Discovery Corp Compuestos basados en 2-amido-tiazol que presentan actividad inhibidora de enzimas que utilizan atp, y composiciones y usos de los mismos
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
CA2580762A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
JP2008513515A (ja) 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
CN101083994A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
AU2006325706B2 (en) * 2005-12-16 2012-03-29 Novartis Ag Control of intraocular pressure using ALK5 modulation agents
WO2008150827A1 (fr) * 2007-05-29 2008-12-11 Smithkline Beecham Corporation Dérivés de naphtyridine en tant qu'inhibiteurs de p13 kinase
US8268874B2 (en) 2008-03-03 2012-09-18 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
WO2009155388A1 (fr) 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Composés d'imidazopyridine et d'imidazopyrazine utilisés comme inhibiteurs de kinase
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6474166B2 (ja) 2014-01-01 2019-02-27 メディベイション テクノロジーズ エルエルシー 化合物及び使用方法
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
BR112019005046A2 (pt) 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
FI3618875T3 (fi) 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
AU2018282747B2 (en) * 2017-06-14 2024-01-18 Trevena, Inc. Compounds for modulating S1P1 activity and methods of using the same
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
EP4061352A4 (fr) 2019-11-19 2024-02-28 Trevena, Inc. Composés et procédés de préparation de composés modulateurs de s1p1
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (fr) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. Dérivés de 5-pyridyle-1,3-thiazole, leur préparation et utilisation
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002502379A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼインヒビターとしての３（５）−ヘテロアリール置換ピラゾール
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
WO1999021555A2 (fr) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Antagonistes des recepteurs de l'adenosine a¿3?
EP1169317B1 (fr) * 1999-04-09 2003-01-15 SmithKline Beecham Corporation Triarylimidazoles
EP1205478A4 (fr) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd INHIBITEURS DE p38MAP KINASE
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
EP1354603A1 (fr) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Co-prescriptions
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1363904A1 (fr) 2001-02-02 2003-11-26 Glaxo Group Limited Pyrazoles utilises comme inhibiteurs du tgf
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JPWO2002062775A1 (ja) 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1402900A1 (fr) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Compositions medicinales
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005539000A (ja) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
AU2003263404A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
OA12929A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
AP2005003260A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel triazole compounds as transforming growth factor (TGF) inhibitors.
WO2004026865A1 (fr) 2002-09-18 2004-04-01 Pfizer Products Inc. Nouveaux composes d'isothiazole et d'isoxazole utilises comme inhibiteurs du facteur de croissance transformant (tgf)

Also Published As

Publication number Publication date
US7273936B2 (en) 2007-09-25
EA200500354A1 (ru) 2005-10-27
CA2499429C (fr) 2010-09-21
UY27978A1 (es) 2004-04-30
PA8582701A1 (es) 2004-04-23
AR041273A1 (es) 2005-05-11
ATE430147T1 (de) 2009-05-15
CR7743A (es) 2005-06-15
PL375975A1 (en) 2005-12-12
MXPA05002332A (es) 2005-06-08
NO20051838L (no) 2005-04-15
US20040110797A1 (en) 2004-06-10
PE20040987A1 (es) 2004-12-27
TW200413362A (en) 2004-08-01
WO2004026863A8 (fr) 2005-04-21
CN1681810A (zh) 2005-10-12
AU2003256003A1 (en) 2004-04-08
BR0314383A (pt) 2005-07-19
JP4518956B2 (ja) 2010-08-04
JP2006502235A (ja) 2006-01-19
EP1542994B1 (fr) 2009-04-29
HRP20050250A2 (en) 2005-10-31
DE60327443D1 (de) 2009-06-10
AP2005003261A0 (en) 2005-03-31
KR20050057415A (ko) 2005-06-16
EP1542994A1 (fr) 2005-06-22
IS7711A (is) 2005-02-24
CO5550473A2 (es) 2005-08-31
ES2323421T3 (es) 2009-07-15
OA12926A (en) 2006-10-13
CA2499429A1 (fr) 2004-04-01
WO2004026863A1 (fr) 2004-04-01

Similar Documents

Publication Publication Date Title
MA27443A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27441A1 (fr) Composes d'imidazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27440A1 (fr) Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)
MA27442A1 (fr) Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27444A1 (fr) Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
NZ542622A (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
MA27156A1 (fr) NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
AP1408A (en) Phenyl yanthine derivatives.
MA30514B1 (fr) Nouveaux composes.
SE9902987D0 (sv) Novel compounds
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA28747B1 (fr) Dérivés de pyridine
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA27661A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
SE9903894D0 (sv) Novel compounds
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1